
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
Digital health philosopher John Nosta returns to talk about the impact of digital health technologies on pharmacy, drug development, and modern medicine.
Digital health philosopher John Nosta returns to talk about the impact of digital health technologies on pharmacy, drug development, and modern medicine.






